Wearables-based walking program in addition to usual physiotherapy care for the management of patients with low back pain at medium or high risk of chronicity: A pilot randomized controlled trial

Hosam Alzahrani, Martin Mackey, Emmanuel Stamatakis, Debra Shirley

1 Department of Physical Therapy, College of Applied Medical Sciences, Taif University, Taif, Saudi Arabia, 2 School of Health Sciences, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia, 3 Charles Perkins Centre, School of Health Sciences, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia, 4 Discipline of Physiotherapy, School of Health Sciences, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia

* halzahrani@tu.edu.sa

Abstract

Background
Although chronic low back pain (LBP) is a leading cause of disability and accounts for large costs, none of the available conventional treatments are clearly more favourable in treating people at increased risk of chronicity.

Objectives
To examine the feasibility and initial efficacy of a wearables-based walking intervention in addition to usual physiotherapy care in people with LBP at risk of chronicity.

Methods
Twenty-six adult participants, diagnosed with non-specific LBP with medium or high risk of chronicity, were recruited from physiotherapy private practices. Participants were randomized into usual physiotherapy care (control, n = 14) and usual physiotherapy care plus a wearables-based walking intervention (experimental, n = 12). The intervention duration was 8 weeks. Feasibility outcomes included recruitment rate, adherence to the intervention, dropout rate, and serious adverse events reporting rate. Other outcomes included disability and pain (primary); and physical activity level, daily walking steps, depression, pain catastrophizing and fear of movement (secondary). The outcomes were assessed at baseline, post-intervention and 26 weeks post-randomization follow-up.

Results
Adherence of experimental participants with the prescribed walking program was moderate. Four participants dropped out during the intervention, and no serious adverse events were
reported. Participants in the experimental group showed significant improvement in pain at 26 weeks (β = -0.38; 95% confidence interval (CI) -0.66, -0.10; P = .013), compared with the control group. No between-group differences were found for disability at any time point and pain immediately post-intervention. Experimental participants demonstrated post-intervention improvement in light-intensity (β = 156.71; 95% CI 86.79, 226.64; P < .001), moderate-intensity physical activity (β = 0.46; 95% CI 0.12, 0.80; P = .012), and daily walking steps (β = 7099.13; 95% CI 4522.93, 9675.32; P < .001). Experimental participants demonstrated post-intervention increase in pain catastrophizing (β = 0.52, 95% CI 0.18, 0.86; P = .006). No between-group differences were found for pain catastrophizing at 26 weeks and other secondary outcomes.

Conclusion
Usual physiotherapy care plus a wearables-based walking intervention program was safe and moderately feasible, and provided significant reduction in pain at 26 weeks as well as increasing the total volume of light- and moderate-intensity physical activity, and daily walking steps immediately post-intervention.

Introduction
Low back pain (LBP) is a major health problem globally; it is one of the most prevalent conditions presenting to health professionals [1, 2] and is the leading cause of years lived with disability [3], imposing a great burden on individuals and communities. While only 23% of people develop chronic non-specific LBP, it accounts for the majority of LBP-related disability and costs [4, 5].

To improve the efficacy and cost-effectiveness of LBP interventions, the STarT Back Screening Tool [6] was developed and validated to stratify patients according to the presence of modifiable physical and psychosocial prognostic variables, thereby promoting targeted treatment [6]. The tool categorizes patients into three levels of risk of developing persistent disabling LBP: low risk, medium risk (which indicates the presence of physical factors and a low level of psychosocial prognostic factors), or high risk (which indicates the presence of high levels of psychosocial prognostic factors, with or without physical factors). People categorized as medium or high risk of chronicity are more disabled by their pain and more likely to have a poor outcome than those at low risk [7]. Since those at low risk have a good prognosis and the highest probability of recovering spontaneously, minimal intervention (i.e., targeting education to remain active and self-management) is recommended [8, 9]. According to current clinical guidelines, no available treatment is clearly more favourable for treating patients at higher risk of chronicity; nevertheless, most of these guidelines recommend treating those at risk with multimodal therapy including cognitive behaviour therapy, exercise therapy and educational interventions [10, 11].

The role of physical activity in improving overall health and reducing risk factors for chronic non-communicable diseases is well documented [12]. Additionally, participating in physical activity has benefits beyond health, including social and economic benefits [13]. Walking is considered one of the simplest and most preferred types of physical activity, as it is functional, safe, accessible, and cost-effective, and it does not require any special equipment [14]. Previous reviews of walking interventions showed a positive effect on LBP outcomes, although research is still limited [15–17]. To address the limitations, these studies...
recommended further research to investigate the appropriate amounts of walking interventions on LBP outcomes. There were also recommendations to use objective self-monitoring devices to both measure the total physical activity level performed and to encourage people to increase their daily walking steps by providing immediate feedback on their progress [16, 17].

Some factors that can influence the success of walking programs, and consequently result in poor adherence to the program, include lack of individual motivation, ineffective goal setting, or inadequate program prescription [18]. There is emerging evidence that physical activity interventions are more effective when they include technology that allows self-monitoring of target behaviours [19, 20]. Current wearable accelerometers such as the Fitbit have features that monitor daily physical activity, set goals, and provide feedback and motivational messages. Fitbit devices have been shown to accurately count steps [21, 22] and have demonstrated the potential to improve a user’s programme adherence and motivation [23]. However, to the best of our knowledge, no study has investigated the effectiveness of the Fitbit device in facilitating a walking intervention for people with LBP.

The objective of this study was to examine the feasibility and initial efficacy of a wearables-based walking intervention, in addition to usual physiotherapy care, among people with medium or high risk of developing LBP chronicity. To examine the feasibility of the wearables-based walking intervention we measured the recruitment rate, adherence to the intervention, dropout rate, and serious adverse events reporting rate. We examined the effects of the intervention using disability and pain as primary outcomes. The secondary outcomes included physical activity level, daily walking steps, depression, pain catastrophizing and fear of movement.

Methods

Study design

The study design was a single-blinded randomized controlled trial. This trial was developed to comply with the guidelines of the Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) and with the Consolidated Standards of Reporting Trials (CONSORT) statement on pilot trial reporting [24]. The intervention was described according to the Template for Intervention Description and Replication (TIDieR) checklist [25]. The protocol of this study was registered prospectively at the Australian New Zealand Clinical Trials Registry (registration number ACTRN12617001404314) and approved by the Human Research Ethics Committee from the University of Sydney (project number 2017/842). The full protocol of the study was published previously in a peer-reviewed journal [26]. Deviations from the study protocol are listed in S1 Table.

Participants

Twenty-six participants were recruited from private physiotherapy practices in Sydney, Australia. The recruited participants were assessed for eligibility by one of the research team (HA) and a practice physiotherapist. The eligibility criteria for participants used in our protocol were presented in Table 1.

Procedure

After confirmation of eligibility and signed informed consent was obtained, baseline outcome measurements were collected. Participants were then randomly allocated to an experimental group (usual physiotherapy care plus a wearables-based walking intervention), or to a control group (usual physiotherapy care alone). The randomization process was performed previously by an independent researcher who was not involved in this study using computer-generated
random numbers. Sealed envelopes were used to conceal the allocation sequence from the investigator screening participants for inclusion. Stratified block randomization was used to ensure fidelity and balance of the usual physiotherapy care given to participants in both groups at each participating clinic. The outcome measurements were administered by a researcher (HA) who guided participants through the whole study period.

**Interventions**

All participants in this study received usual physiotherapy care which was provided by registered physiotherapists. The physiotherapy management provided was at the choice of the physiotherapists who determined the treatment pragmatically based on clinical reasoning. The usual physiotherapy care was a combination of, for example, strengthening exercises, stabilisation exercises, home exercises, manual therapy and education.

Participants allocated to the control group received eight weeks of usual physiotherapy care (as described above). They were also given instructions to maintain their usual physical activity level during the treatment period.

Participants randomized to the experimental group received an eight-week wearables-based walking intervention provided by one of the researchers (HA) in addition to the usual physiotherapy care. The wearables-based walking intervention was developed for patients with LBP, using physical activity guidelines [28, 29] in order to assist them maintain their usual activities, and to improve their adherence with the prescribed walking intervention. The intervention consisted of: 1) wearable device, 2) access to the 10,000 Steps website (www.10000steps.org.au) [30], and 3) progressive walking program.

During baseline measurement, all participants were also required to wear a wearable device (Fitbit Flex) for seven continuous days, to measure the total number of habitual walking steps per week [31]. Participants were not given any access to the number of walking steps attained during the baseline measurement. After conducting the randomization process, the baseline

| Table 1. Eligibility criteria for participants. |
|-----------------------------------------------|
| **Inclusion criteria**                         |
| Aged ≥ 18 years old                           |
| Diagnosed with non-specific LBP by a physiotherapist |
| Categorized as being at medium or high risk of chronicity using the STarT Back Screening Tool [6] |
| Classified as insufficiently physically active (those who engage in less than 150 minutes/week of moderate intensity, or less than 75 minutes/week of vigorous intensity or an equivalent combination of the two intensities of physical activity as determined by IPAQ [27]) |
| Accessibility to internet                     |
| Readiness and ability to participate in physical activity as determined by PAR-Q. Those deemed not fit to participate in physical activity by the PAR-Q or aged over 69 years, will need a clearance from their medical practitioner before engaging in the walking intervention |

| **Exclusion criteria**                         |
| Diagnosed with a condition (cardiovascular diseases e.g., myocardial infarction, embolism, or uncontrolled diabetes; orthopaedic impairments; balance problems) that prevent participation in physical exercise |
| Diagnosed with serious spinal pathologies (e.g., fractures, tumours or inflammatory diseases such as ankylosing spondylitis) |
| Diagnosed with neurological compromise (e.g., spinal nerve compromise or cauda equina syndrome) |
| Pregnancy                                      |

LBP, low back pain; IPAQ, International Physical Activity Questionnaire; PAR-Q, Physical Activity Readiness Questionnaire

https://doi.org/10.1371/journal.pone.0256459.t001
average daily walking steps (measured by Fitbit) for participants allocated in the experimental group were calculated by dividing the total weekly number of walking steps by seven (total weekly steps/7). In the first week of the intervention the target for each participant was ‘the average daily walking steps plus 10%’ and each week the target of the previous week was progressed by a further 10%. To comply with current physical activity guidelines, participants were also asked to walk the prescribed number of steps at a moderate intensity (i.e., brisk walking, 100 steps/min) [32–35]. Participants were asked to carry out the prescribed walking program on at least five days per week for eight weeks.

Participants randomized to the experimental group were given the Fitbit wearable device and attended a training session delivered by the same researcher (HA). The training session involved installing and setting up the Fitbit wearable device and account, registering the participant in the 10,000 Steps website and synchronising the device with the Fitbit account. Participants were also provided with instructions of using the device and account including monitoring step counts as well as other features. Participants were instructed to wear the Fitbit device continuously during the day, even during showering or while engaging in any water-based activities, and take it off while sleeping.

The Fitbit is a waterproof monitoring device that can be worn as a wristband for 24 hours, which can be more convenient for participants than other devices worn on the waist. The Fitbit contains a tri-axial accelerometer, which has been shown to be accurate and valid in measuring physical activity and quantifying steps [21, 22, 36]. The fully charged Fitbit battery lasts for approximately 5 days (detailed information on the Fitbit Flex device can be found on https://www.fitbit.com/global/us/home). The Fitbit wearable device enabled participants to monitor their progress in meeting the target number of steps each day. Further, the Fitbit wearable device acted as a motivational feedback tool providing information via the Fitbit application on the number of walking steps attained. The 10,000 Steps website is a non-profit promotion web-based platform that was developed by Central Queensland University in Australia to increase the physical activity level of the general community and it can automatically connect and synchronise with the Fitbit account. We used this website to encourage participants to track and monitor progress in achieving the daily target, use the Fitbit device and share their progress with other participants. Also, it enabled the investigator to monitor and track the participants’ progress and keep in contact with them. The website has high levels of usability. Further details about the conceptual basis for wearables-based Walking Intervention and development can be found elsewhere [26].

Outcomes

The protocol feasibility was evaluated by measuring the recruitment rate, dropout rate, participant’s adherence with the walking intervention, and occurrence of serious adverse events. The adherence with the walking intervention was measured using the Fitbit wearable device during the treatment period (8 weeks) by assessing the number of steps attained each day. Adherence with the prescribed walking intervention was calculated by dividing the average attained walking steps per day by the average target walking steps in that week and expressing it as a percentage.

All primary and secondary outcomes were measured at baseline (week 0), post-intervention (week 9) and post-randomization follow-up (week 26).

The primary outcomes were disability and pain. Disability was measured by the 10-item modified Oswestry Disability Index (ODI), with higher scores indicating greater disability (range, 0–100) [37]. The ODI has demonstrated a good validity, reliability and responsiveness for detecting change in disability in people with LBP [37, 38]. The worst pain intensity was
measured in the past 24 hours by the Visual Analogue Scale (VAS), on scale from 0 (no pain) to 10 (worst pain) [39]. The VAS is a valid and reliable tool for assessing pain in participants with LBP [40].

Secondary outcomes included measures of physical activity intensity (light-, moderate-, and vigorous-intensity) and walking steps as well as depression, pain catastrophizing and fear of movement. Physical activity level and walking steps were measured during waking hours over one week with the Axivity AX3 (Newcastle upon Tyne, UK; product website: http://axivity.com/product/ax3), worn on non-dominant wrist. The Axivity has been shown to be accurate and valid in assessing physical activity [41, 42] and measuring walking steps [43–45]. Depression was measured by the 21-item Beck Depression Inventory (BDI) [46], which has a good internal consistency and good content validity [47]. Participants’ thoughts and feelings about pain were measured by the 13-item Pain Catastrophizing Scale (PCS) [48], which has been shown to be reliable and valid [49, 50]. Fear of movement was measured by the 17-item Tampa Scale for Kinesiophobia (TSK); this tool has good validity and reliability in assessment the fear of movement resulting from feeling of vulnerability to re-injury in participants with pain [51, 52].

The subjective data (disability, pain, depression, pain catastrophizing and fear of movement) were collected and administered using Research Electronic Data Capture (REDCap) [53]. Further details concerning the outcomes can be found in the study protocol [26].

Axivity AX3 data extraction

The Axivity was set up to capture data for seven continuous days at 100Hz with a dynamic range of ±8g. Physical activity intensity levels (light, moderate and vigorous) were extracted from the Axivity device using OMGUI software (GITHUB, University of Newcastle) and the standard thresholds were used to aggregate data into light (≥1.5 metabolic equivalent (MET), <4 MET), moderate (≥4 MET, <7 MET), and vigorous (≥7 MET) activity [54]. The walking bouts were extracted using MATLAB program (version R2018a) with threshold of 60s. The average number of total steps per day was calculated by summing up the number of steps in that week and then dividing the total number of steps by seven [55]. The algorithm used by MATLAB program is based on a method presented in previous studies [56]. For a day to be ‘valid’ for inclusion in the analyses, participants had to have worn the Axivity device for at least 8 hours. The wear time estimation was extracted using OMGUI. The algorithm used by OMGUI is based on a method proposed in a previous study [57]. All participants with at least one valid day of Axivity wear have been included in the analyses. However, the majority of participants (baseline: 99%, post-intervention: 100%, 26 weeks: 77%) had at least 3 valid days of wear.

Sample size

Although a pilot RCT does not require estimating the sample size [58], a minimum of 12 participants per group is recommended to ensure scientific validity of the pilot trial results [59, 60]. Therefore, the present pilot RCT would need a minimum of 24 participants with 12 participants per group. Furthermore, the results of this pilot trial provide information on the mean difference between groups and standard deviation (SD) necessary for use in the calculation of the sample size for future fully powered trial.

Statistical analysis

Demographic variables, clinical characteristics and outcome measures were displayed by means (standard deviation (SD)) or median (interquartile range (IQR)). The treatment effects were examined using linear regression. Assumptions of linear regression were assessed and met. The normality of outcomes was examined using Shapiro-Wilk test, and the variables that
were not normally distributed were log transformed. The statistical analysis followed the intention-to-treat principle in which all participants were analyzed in the groups to which they were randomized, regardless of whether they withdrew from their allocation [61]. Missing data were replaced with the mean value for each item [62]. The analysis was conducted in consultation with an expert statistician who was blinded to the treatment allocation. Data were analyzed using IBM Statistical Package for Social Sciences (SPSS) version 22 [63].

Results

Flow of participants through the study

A total of 63 participants with medium or high risk of chronicity of LBP were screened for inclusion between December 2017 and November 2018. Twenty-six participants were eligible to be included in the study. Twenty-two participants have completed the study and four participants (1 from the experimental group and 3 from the control group) dropped out during the intervention period: two for personal reasons and two were not interested in completing the study. Flow of participants through the study is shown in Fig 1.

Characteristics of participants

Twenty-six participants (11 females (42.3%)) with a mean age of 43.6 years, were randomized to either the experimental group (n = 12) or control group (n = 14). Table 2 presents the baseline characteristics of participants by study arm.

Protocol feasibility

The trial protocol was deemed safe and moderately feasible. Adherence of participants in the experimental group with the prescribed walking program was moderate. Participants in the

![Flow of participants through the trial](https://doi.org/10.1371/journal.pone.0256459.g001)
experimental group adhered to 67.1% of the prescribed walking program. There were no serious adverse events reported in this study. However, there was difficulty in recruiting participants as we were only able to recruit 26 participants.

Adherence with walking intervention program

Participants in the experimental group (n = 11) adhered to 67.1% (range = 56.3) of the prescribed walking program. The median percentage adherence of participants to the walking program decreased by an average of 7.7% ($P < .001$) each week throughout the program. Participants adhered to 94.2% (range = 106) of the prescribed walking program in the first week followed by 90.8% (range = 109) and 90.5% (range = 141.1) in the second and third weeks, respectively. The median percentage adherence started to decline from the fourth week until it reached 45.7% (range = 82.2) in the last week of the program (Fig 2).

The correlation of outcomes with the participants’ adherence to the prescribed walking program is displayed in S2 Table. There was a strong, inverse correlation between treatment adherence and pain intensity at 26 weeks follow-up ($r = -0.665; n = 11; P = .026$), but not with the other outcomes.

Primary outcomes

There were no between-group differences in disability post-intervention ($\beta = -.05$, 95% CI -0.30, 0.20; $P = .670$) or at 26 weeks ($\beta = -.15$, 95% CI -0.52, 0.21; $P = .374$), or in pain post-intervention ($\beta = -.11$, 95% CI -0.33, 0.10; $P = .273$). However, participants in the
experimental group had significantly lower pain at 26 weeks ($\beta = -0.38$, 95% CI -0.66, -0.10; $P = .013$), compared with the control group. Table 3 shows the mean or median scores and differences between groups post-intervention and at 26 weeks for all outcomes.

**Secondary outcomes**

Participants in the experimental group demonstrated improvement in light-intensity physical activity post-intervention ($\beta = 156.71$, 95% CI 86.79, 226.64; $P < .001$) and moderate-intensity physical activity post-intervention ($\beta = 0.46$, 95% CI 0.12, 0.80; $P = .012$), compared with the control group. However, these improvements were no longer statistically significant at 26 weeks. We found no significant differences between groups in vigorous-intensity at any time point. Participants in the experimental group demonstrated a significant increase in number of daily walking steps post-intervention ($\beta = 7099.13$, 95% CI 4522.93, 9675.32; $P < .001$) but not at 26 weeks, compared with the control group (Table 3).

Participants in the experimental group had significantly higher pain catastrophizing post-intervention ($\beta = 0.52$, 95% CI 0.18, 0.86; $P = .006$), compared with the control group. However, there were no differences between groups for pain catastrophizing at 26 weeks and the other secondary outcomes of depression, and fear of movement at any time point (Table 3).

**Discussion**

This study found that the addition of a wearables-based walking intervention to usual physiotherapy care was safe and moderately feasible, as well as effective in improving pain at 26 weeks, and increasing light- and moderate-intensity physical activity and daily walking steps immediately post-intervention although these improvements were not sustained at 26 weeks. However, participants in the experimental group had significantly higher pain catastrophizing immediately post-intervention, compared with the control group. There were no between-group differences in pain catastrophizing at 26 weeks, and disability, depression, fear of movement, and vigorous-intensity physical activity at any time point. However, as this study is a pilot trial with a small sample size, no observable significant effects were expected to be seen in the outcomes measures. It should also be noted that including a relatively small sample size increased the possibility for a type 2 error.
Table 3. Scores for primary and secondary outcomes and differences between groups.

| Outcomes                              | Experimental (n = 12) | Control (n = 14) | Unadjusted Between-Group Difference | Adjusted Between-Group Difference |
|---------------------------------------|-----------------------|------------------|-------------------------------------|----------------------------------|
|                                       | Mean (SD) a           | Mean (SD) a      | β                                   | 95% CI                           | P      | β                           | 95% CI                           | P      |
| Primary Outcomes                      |                       |                  |                                     |                                  |        |                             |                                  |        |
| Disability (ODI score (0–100)) b, c   |                       |                  |                                     |                                  |        |                             |                                  |        |
| Baseline                              | 17 (28)               | 30 (39)          |                                     |                                  |        |                             |                                  |        |
| 9 weeks                               | 14 (13)               | 19.55 (11)       | -0.07                               | -0.23, 0.09                      | 0.352  | -0.05                        | -0.30, 0.20                      | 0.670  |
| 26 weeks                              | 12.64 (11)            | 19.45 (11)       | -0.23                               | -0.48, 0.03                      | 0.075  | -0.15                        | -0.52, 0.21                      | 0.374  |
| Pain (VAS score (0–10)) b, c          |                       |                  |                                     |                                  |        |                             |                                  |        |
| Baseline                              | 4 (2)                 | 5 (2)            |                                     |                                  |        |                             |                                  |        |
| 9 weeks                               | 3 (3)                 | 3 (1)            | -0.01                               | -0.21, 0.19                      | 0.944  | -0.11                        | -0.33, 0.10                      | 0.273  |
| 26 weeks                              | 1 (2)                 | 3.36 (4)         | -0.28                               | -0.54, -0.03                     | 0.033  | -0.38                        | -0.66, -0.10                     | 0.013  |
| Secondary Outcomes                    |                       |                  |                                     |                                  |        |                             |                                  |        |
| Physical activity (minutes/day)       |                       |                  |                                     |                                  |        |                             |                                  |        |
| Light                                 |                       |                  |                                     |                                  |        |                             |                                  |        |
| Baseline                              | 269.39 (104.87)       | 301.65 (86.93)   |                                     |                                  |        |                             |                                  |        |
| 9 weeks                               | 314.77 (137.68)       | 244.24 (126.29)  | 70.53                               | -36.35, 177.41                   | 0.186  | 156.71                       | 86.79, 226.64                     | <0.001 |
| 26 weeks                              | 269.76 (110.75)       | 271.48 (116.85)  | -1.72                               | -94.35, 90.92                    | 0.970  | 45.48                        | -55.10, 146.06                    | 0.350  |
| Moderate b, c                          |                       |                  |                                     |                                  |        |                             |                                  |        |
| Baseline                              | 80.93 (28.01)         | 68.16 (45.22)    |                                     |                                  |        |                             |                                  |        |
| 9 weeks                               | 103.13 (46.49)        | 84.95 (77.48)    | 0.18                                | -0.14, 0.49                      | 0.250  | 0.46                         | 0.12, 0.80                        | 0.012  |
| 26 weeks                              | 84.41 (27.25)         | 76.09 (50.81)    | 0.17                                | -0.10, 0.45                      | 0.205  | 0.30                         | -0.05, 0.65                       | 0.086  |
| Vigorous b, c                         |                       |                  |                                     |                                  |        |                             |                                  |        |
| Baseline                              | 0.36 (1.11)           | 0.29 (1.22)      |                                     |                                  |        |                             |                                  |        |
| 9 weeks                               | 1 (1.54)              | 0.84 (1.42)      | 0.06                                | -0.26, 0.39                      | 0.683  | 0.06                         | -0.40, 0.52                       | 0.778  |
| 26 weeks                              | 1.21 (1.58)           | 0.95 (2.01)      | -0.09                               | -0.60, 0.43                      | 0.735  | 0.15                         | -0.44, 0.73                       | 0.573  |
| Walking steps (steps/day)             |                       |                  |                                     |                                  |        |                             |                                  |        |
| Baseline                              | 12998.30 (4217.78)    | 13563.10 (5968.27)|                                     |                                  |        |                             |                                  |        |
| 9 weeks                               | 15647.42 (5813.38)    | 11978.75 (6516.98)| 3668.66                             | -1368.91, 8706.23                | 0.146  | 7099.13                      | 4522.93, 9675.32                  | <0.001 |
| 26 weeks                              | 13770.09 (5517.18)    | 11600.6131 (5542.77)| 2169.484                           | -2321.37, 6660.33                | 0.329  | 4582.37                      | -124.38, 9289.12                  | 0.056  |
| Depression (BDI score (0–63)) b, c    |                       |                  |                                     |                                  |        |                             |                                  |        |
| Baseline                              | 7.50 (11)             | 13.50 (20)       |                                     |                                  |        |                             |                                  |        |
| 9 weeks                               | 8.59 (11)             | 8.36 (10)        | 0.01                                | -0.36, 0.38                      | 0.959  | 0.11                         | -0.34, 0.56                       | 0.616  |
| 26 weeks                              | 6.37 (6)              | 10.32 (7)        | -0.23                               | -0.50, 0.04                      | 0.094  | -0.19                        | -0.54, 0.15                       | 0.243  |
| Pain Catastrophizing (PCS score (0– 52)) b, c |      |                  |                                     |                                  |        |                             |                                  |        |
| Baseline                              | 18.50 (24)            | 17 (32)          |                                     |                                  |        |                             |                                  |        |
| 9 weeks                               | 13 (11)               | 9.50 (10)        | 0.23                                | -0.14, 0.59                      | 0.208  | 0.52                         | 0.18, 0.86                        | 0.006  |
| 26 weeks                              | 14.55 (21)            | 10.91 (21)       | 0.10                                | -0.35, 0.55                      | 0.654  | 0.32                         | -0.14, 0.78                       | 0.151  |
| Kinesiophobia (TSK score (17–68))     |                       |                  |                                     |                                  |        |                             |                                  |        |
| Baseline                              | 39.92 (7.79)          | 40.43 (10.56)    |                                     |                                  |        |                             |                                  |        |
| 9 weeks                               | 40.82 (8.88)          | 37.09 (7.30)     | 3.73                                | -2.82, 10.27                     | 0.251  | 2.22                         | -3.98, 8.42                       | 0.457  |

(Continued)
This pilot trial showed that the prescribed walking intervention program for participants with LBP with medium or high risk of chronicity is safe and moderately feasible. We observed a moderate rate of adherence, a low dropout rate, and observed no serious adverse events. Possible reasons for dropping out the study might be due to participants lacking the desire/motivation to commit to some or all of the trial tasks, for example filling in the questionnaires and engaging in physical activity interventions. In addition, there was difficulty in recruiting participants in this study. One suggested reason for the low recruitment rate was that because this study was unfunded and we were unable to pay for the overall treatment sessions and travelling costs.

The significant reduction in pain might be explained by the increase in physical activity level and walking steps among participants in the experimental group, where the estimated increases in daily walking steps from baseline was 2649 steps (20%) post-intervention and 772 steps (6%) at 26 weeks. This finding is consistent with the study published by McDonough, Tully [55] which found that participants who received pedometer driven walking intervention increased their daily walking steps at eight weeks by 2776 from baseline and had a greater improvement in disability and pain at 24 weeks, compared with those who received education/advice only. Furthermore, the study published by Krein, Kadri [64] found an increase of approximately 700 daily walking steps (measured by a pedometer) and reduction in pain at 24 weeks in the intervention participants. The delay in the effects of the experimental intervention in reduction of pain remain to be investigated; however, participants in the experimental group had increase in pain catastrophizing immediately post-intervention which might delay the recovery [65]. Various studies showed that pain catastrophizing is associated with more intense experience of pain and poor treatment outcomes [66–68]. Thus, including additional interventions (e.g., cognitive behavioural intervention) to address the negative perceptions of pain (pain catastrophizing) can help in avoiding delayed recovery and chronicity [65, 69]. To our knowledge, there is no study investigated the effectiveness of physical activity interventions in reducing pain catastrophizing in people with chronic LBP. Therefore, a future trial investigating a combined wearables-based walking program and cognitive behavioural intervention in management people with medium or high risk of LBP chronicity is required.

Although the wearables-based walking intervention program was effective in increasing physical activity levels immediately post-intervention, there was no effect on disability, depression and fear of movement at any time point. This finding was inconsistent with a previous trial by Krein, Kadri [64] which found that the internet-mediated walking intervention was effective in reducing disability at 24 weeks. However, the participants included in that study

| Outcomes | Experimental (n = 12) | Control (n = 14) | Unadjusted Between-Group Difference | Adjusted Between-Group Difference a |
|----------|----------------------|-----------------|------------------------------------|-----------------------------------|
| 26 weeks | 43.18 (8.49)         | 36.36 (8.41)    | 6.82                              | -0.04, 13.68                      |

* p < 0.05, **p < 0.001

Abbreviations: BDI, Beck Depression Inventory; IQR, interquartile range; ODI, Oswestry Disability Index; PCS, Pain Catastrophizing Scale; SD, standard deviation; TSK, Tampa Scale for Kinesiophobia; VAS, Visual Analogue Scale; y, years.

a Data are reported as mean (SD), unless otherwise indicated.
b Data are reported as median (IQR).
c Variable was log transformed as their distribution deviated from normal.
d Adjusted for baseline values of primary and secondary outcomes.

Note: There were 12, 11, and 11 participants in the experimental group with available data at baseline, 9-weeks, and 26-weeks follow-ups, respectively. There were 14, 11, and 11 participants in the control group with available data at baseline, 9-weeks, and 26-weeks follow-ups, respectively.

https://doi.org/10.1371/journal.pone.0256459.t003
were classified as inactive at baseline (mean < 5000 steps/day, measured by pedometer) while participants included in our study were classified as active at baseline (mean > 10,000 steps/day, measured by Axivity), suggesting there was a possibility of ceiling effect. Therefore, inactive people might be more likely to show improvements in physical activity levels and walking steps. A future trial investigating the effectiveness of the wearables-based walking intervention program in inactive people is recommended.

With the proven benefits of physical activity for overall health [12, 17], the focus of this intervention was on increasing amount and intensity of habitual physical activity. The wearables-based walking intervention program was effective in motivating participants in the experimental group and increasing their physical activity level. This result is important as the existing literature indicated the role of physical activity in reducing the risk of progression to chronicity in LBP [70, 71]. The average daily walking steps increased significantly in the experimental group post-intervention, compared with the control group. Estimated increase in daily walking steps in the experimental group from baseline to post-intervention was 2649 steps. In contrast, the estimated decrease in daily walking steps in the control group from baseline to post-intervention was 1585 steps. Additionally, the light- and moderate-intensity physical activity increased significantly in the experimental group post-intervention compared with the control group, with an adjusted between-group difference of 157 minutes/day and 43 minutes/day, respectively. Interestingly, there was no between-group difference in their level of vigorous-intensity physical activity. One explanation of that is might be because of the focus of the intervention program on moderate-intensity physical activity and walking steps.

We found a strong, negative correlation between intervention’s adherence and pain intensity at 26 weeks follow-up. This finding indicates that improving participant’s adherence to the intervention is likely to affect the success of the intervention program. The walking intervention program was moderately feasible in improving adherence with the prescribed walking intervention program. Participants in the experimental group adhered to 67.1% of the prescribed walking intervention. However, the median percentage adherence declined gradually from the fourth week until reached 45.7% in the last week of the program. This finding was in agreement with a previous study which found that the mean percentage adherence (measured by a pedometer) of chronic LBP participants with the 8-week progressive walking program was 70% [55]. Consistent adherence to treatment can be challenging, suggesting that additional strategies to promote adherence can help to maintain consistent engagement with the intervention program. One strategy is using new models of trackers with screens allowing participants to monitor their progress in real time using the watch without the need to go to the application.

We also observed that participants preferred to monitor their physical activity progress using the mobile application rather than using the website. Participants used the Fitbit application to monitor their physical activity progress more often than the 10,000 steps website. Therefore, the influence of the website in motivating participants to monitor their progress and adherence to the treatment might be limited. That might be one of the potential explanations for the gradually decrease in adherence to intervention during the eight-week intervention program (measured using Fitbit).

All participants were instructed to wear the Fitbit for the first week and the Axivity for three separate weeks during the study. This may increase the burden on participants, and consequently increase the chance of them dropping out of study. Furthermore, participants randomized to the experimental group were also instructed to wear the Fitbit for two months during the intervention period. Therefore, to decrease the burden on participants and for their comfort during the study, they were instructed to place it on their wrist. However, placing the wearable devices (Axivity and Fitbit) on the wrist may have resulted in more movement being detected during upper arm movement when the wrist is involved, than during walking [72].
This study has several strengths which include: 1) measuring the change in physical activity level and daily walking steps for participants objectively using the Axivity device; 2) prescribing a progressive walking program that is tailored to each participant with the aim of motivating participants and encouraging them to increase their activity level; and 3) measuring the participants’ adherence to the intervention objectively using the Fitbit device.

This study had several methodological limitations. First, participants met the inclusion criteria for the study if they were classified as inactive using the IPAQ as an initial screen for level of physical activity. As a self-report questionnaire, the IPAQ is likely to be subject to recall bias, as none of the included participants were classified as inactive at baseline when measured by the accelerometer. Therefore, using accelerometer as an initial screen is recommended in future research. Second, our sample size was relatively small and underpowered to detect significant improvements in our specified outcomes. Third, self-selection may be a factor in that people who already physically active may have been more likely to volunteer for the trial. Fourth, overweight and/or obese participants were not excluded from this study, which might have a significant impact on the outcomes of low back pain and physical activity.

Conclusion

Our study has shown the efficacy of the addition of the wearables-based walking intervention to usual physiotherapy care in management participants with medium or high risk of LBP chronicity. Furthermore, a wearables-based walking program is moderately feasible and safe to carry out in individuals with LBP with medium or high risk of chronicity. In addition, participants in the experimental group demonstrated improvements in pain at 26 weeks, as well as greater increases in light- and moderate-intensity physical activity and walking steps immediately post-intervention. These preliminary findings suggest that physical activity may play an important role in alleviating some of the consequences of chronic LBP. However, there was no effect on pain catastrophizing at 26 weeks, and disability, depression, fear of movement, and vigorous-intensity physical activity at any time point.

Supporting information

S1 Table. Deviations from the study protocol.
(DOCX)

S2 Table. Bivariate correlation of outcomes with participants adherence to the prescribed walking program (n = 11).
(DOCX)

S1 Protocol.
(DOCX)

S1 Checklist. CONSORT checklist.
(DOC)

S1 File. Dataset.
(XLSX)

Acknowledgments

We are grateful to Julie Godfrey, NSW State Manager for Zenitas Healthcare Limited (Zenitas) / Lifecare; Ali Jadid, Manager for Primary PhysioCare Pty Ltd; Ghassan Hijazi, Manager for
Hydroactive Physio Clinic; Abdul-Raouf Baghdadi, Manager for Masnad Health Clinic; for their help in conducting this study in their clinics in NSW, Australia.

The authors would like to thank John Eisenhuth for his help in setting up and extracting data from the Axivity devices, as well as Professor Deborah Black for providing advice on the analyses.

Thanks also to Marina B Pinheiro for providing advice on the intervention program and performing the randomization process using computer-generated random numbers.

Hosam Alzahrani acknowledges Taif University Researchers Supporting Project number (TURSP-2020/238), Taif University, Taif, Saudi Arabia.

Author Contributions

Conceptualization: Hosam Alzahrani, Martin Mackey, Emmanuel Stamatakis, Debra Shirley.
Data curation: Hosam Alzahrani.
Formal analysis: Hosam Alzahrani.
Methodology: Hosam Alzahrani, Martin Mackey, Emmanuel Stamatakis, Debra Shirley.
Project administration: Hosam Alzahrani, Debra Shirley.
Resources: Hosam Alzahrani, Martin Mackey, Debra Shirley.
Supervision: Hosam Alzahrani, Martin Mackey, Debra Shirley.
Validation: Hosam Alzahrani, Debra Shirley.
Visualization: Hosam Alzahrani.
Writing – original draft: Hosam Alzahrani, Martin Mackey, Emmanuel Stamatakis, Debra Shirley.
Writing – review & editing: Hosam Alzahrani, Martin Mackey, Emmanuel Stamatakis, Debra Shirley.

References

1. Walker BF. The prevalence of low back pain: a systematic review of the literature from 1966 to 1998. Journal of spinal disorders. 2000; 13(3):205–17. Epub 2000/06/29. https://doi.org/10.1097/00002517-200006000-00003 PMID: 10872758.
2. Hoy D, Bain C, Williams G, March L, Brooks P, Blyth F, et al. A systematic review of the global prevalence of low back pain. Arthritis and rheumatism. 2012; 64(6):2028–37. Epub 2012/01/11. https://doi.org/10.1002/art.34347 PMID: 22231424.
3. Vos T, Abajobir AA, Abate KH, Abbafati C, Abbas KM, Abd-Allah F, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017; 390(10100):1211–59. https://doi.org/10.1016/S0140-6736(17)32154-2 PMID: 28919117
4. Meucci RD, Fassa AG, Faria NMX. Prevalence of chronic low back pain: systematic review. Revista de saude publica. 2015; 49:1-. https://doi.org/10.1590/s0034-8910.2015049005472 PMID: 25741653.
5. Gore M, Sadosky A, Stacey BR, Tai K-S, Leslie D. The burden of chronic low back pain: clinical comorbidities, treatment patterns, and health care costs in usual care settings. Spine. 2012; 37(11):E668–E77. https://doi.org/10.1097/BRS.0b013e318241e5de PMID: 22146287
6. Hill JC, Dunn KM, Lewis M, Mullis R, Main CJ, Foster NE, et al. A primary care back pain screening tool: identifying patient subgroups for initial treatment. Arthritis and rheumatism. 2008; 59(5):632–41. Epub 2008/04/29. https://doi.org/10.1002/art.23563 PMID: 18438893.
7. Robinson HS, Dagfinrud H. Reliability and screening ability of the StarT Back screening tool in patients with low back pain in physiotherapy practice, a cohort study. BMC Musculoskeletal Disorder. 2017; 18(1):232. Epub 2017/06/02. https://doi.org/10.1186/s12891-017-1553-x PMID: 28569152; PubMed Central PMCID: PMC5452390.
8. Foster NE, Mullis R, Hill JC, Lewis M, Whitehurst DG, Doyle C, et al. Effect of stratified care for low back pain in family practice (IMPaCT Back): a prospective population-based sequential comparison. Ann Fam Med. 2014; 12(2):102–11. Epub 2014/03/13. https://doi.org/10.1370/afm.1625 PMID: 24615305; PubMed Central PMCID: PMC3948756.

9. NSW Agency for Clinical Innovation. Management of people with acute low back pain: model of care2016.

10. O’Sullivan P. It’s time for change with the management of non-specific chronic low back pain. Br J Sports Med. 2012; 46(4):224–7. Epub 2011/08/09. https://doi.org/10.1136/bjsm.2010.081638 PMID: 21821612.

11. Koes BW, van Tulder MW, Thomas S. Diagnosis and treatment of low back pain. BMJ. 2006; 332(7555):1430–4. Epub 2006/06/17. https://doi.org/10.1136/bmj.332.7555.1430 PMID: 16777886; PubMed Central PMCID: PMC1479671.

12. Warburton DE, Nicol CW, Bredin SS. Health benefits of physical activity: the evidence. Canadian Medical Association Journal. 2006; 174(6):801–9. Epub 2006/03/15. https://doi.org/10.1503/cmaj.051351 PMID: 16534088; PubMed Central PMCID: PMC1402378.

13. Breuer C, Rutgers H, Collins C. EuropeActive. The future of health & fitness: a plan for getting europe active by 2025: BlackBoxPubl; 2014.

14. Siegel PZ, Brackbill RM, Heath GW. The epidemiology of walking for exercise: implications for promoting activity among sedentary groups. Am J Public Health. 1995; 85(5):706–10. Epub 1995/05/01. https://doi.org/10.2105/ajph.85.5.706 PMID: 7733433; PubMed Central PMCID: PMC1615430.

15. Vanti C, Andreatta S, Borghi S, Guccione AA, Pillastri P, Bertozzi L. The effectiveness of walking versus exercise on pain and function in chronic low back pain: a systematic review and meta-analysis of randomized trials. Disabil Rehabil. 2017; 1–11. Epub 2017/12/07. https://doi.org/10.1080/09638288.2017.1410730 PMID: 29207885.

16. Sitthipornvorakul E, Klimson T, Sihawong R, Janwantanakul P. The effects of walking intervention in patients with chronic low back pain: a meta-analysis of randomised controlled trials. Musculoskelet Sci Pract. 2018; 34:38–46. Epub 2017/12/20. https://doi.org/10.1016/j.msds.2017.12.003 PMID: 29257996.

17. Alzahrani H, Mackey M, Stamatakis E, Pinheiro MB, Wicks M, Shirley D. The effectiveness of incidental physical activity interventions compared to other interventions in the management of people with low back pain: a systematic review and meta-analysis of randomised controlled trials. Phys Ther Sport. 2019; 36:34–42. https://doi.org/10.1016/j.ptsp.2018.12.008 PMID: 30620922.

18. Robison J, Rogers MA. Adherence to exercise programmes. Sports Med. 1994; 17(1):39–52. https://doi.org/10.2165/00007256-199417010-00004 PMID: 8153498.

19. Bravata DM, Smith-Spangler C, Sundaram V, Gienger AL, Lin N, Lewis R, et al. Using pedometers to increase physical activity and improve health: a systematic review. JAMA. 2007; 298(19):2296–304. Epub 2007/11/22. https://doi.org/10.1001/jama.298.19.2296 PMID: 18029834.

20. Ogilvie D, Foster CE, Rothnie H, Cavil N, Hamilton V, Fitzsimons CF, et al. Interventions to promote walking: systematic review. BMJ. 2007; 334(7565):1204. Epub 2007/06/02. https://doi.org/10.1136/bmj.39198.722270.BE PMID: 17540909; PubMed Central PMCID: PMC1889976.

21. Diaz KM, Krupka DJ, Chang MJ, Peacock J, Ma Y, Goldsmith J, et al. FITBIT®: an accurate and reliable device for wireless physical activity tracking. International journal of cardiology. 2015; 185:138–40. https://doi.org/10.1016/j.ijcard.2015.03.038 PubMed PMID: PMC4406840. PMID: 25795203.

22. Evenson KR, Goto MM, Furberg RD. Systematic review of the validity and reliability of consumer-wearable activity trackers. Int J Behav Nutr Phys Act. 2015; 12:159. Epub 2015/12/20. https://doi.org/10.1186/s12966-015-0314-1 PMID: 26684758; PubMed Central PMCID: PMC4683756.

23. Cadmus-Bertram L, Marcus BH, Patterson RE, Parker BA, Morey BL. Use of the fitbit to measure adherence to a physical activity intervention among overweight or obese, postmenopausal women: self-monitoring trajectory during 16 weeks. JMIR Mhealth Uhealth. 2015; 3(4):e96. Epub 2015/11/21. https://doi.org/10.2196/mhealth.4229 PMID: 26586418; PubMed Central PMCID: PMC4705008.

24. Eldridge SM, Chan CL, Campbell MJ, Bond CM, Hopewell S, Thrane L, et al. CONSORT 2010 statement: extension to randomised pilot and feasibility trials. BMJ. 2016; 355:i5239. https://doi.org/10.1136/bmj.i5239 PMID: 27777223.

25. Hoffmann TC, Glasziou PP, Boutron I, Milne R, Perera R, Moher D, et al. Better reporting of interventions: template for intervention description and replication (TIDieR) checklist and guide. BMJ. 2014; 348:g1687. Epub 2014/03/13. https://doi.org/10.1136/bmj.g1687 PMID: 24608605.

26. Alzahrani H, Mackey M, Stamatakis E, Pinheiro MB, Shirley D. Accelerometer-based facilitated walking program in addition to usual care for the management of patients with low back pain at medium or high risk of chronicity: a randomised controlled trial protocol. Int J Clin Trials. 2019; 6(1):10. Epub 2019-01-25. https://doi.org/10.18203/2349-3259.ijct20190258
27. Craig CL, Marshall AL, Sjostrom M, Bauman AE, Booth ML, Ainsworth BE, et al. International physical activity questionnaire: 12-country reliability and validity. Medicine and science in sports and exercise. 2003; 35(6):1381–95. Epub 2003/08/06. https://doi.org/10.1249/01.MSS.0000078924.61453.FB PMID: 12900694.

28. Koes BW, van Tulder M, Lin CW, Macedo LG, McAuley J, Maher C. An updated overview of clinical guidelines for the management of non-specific low back pain in primary care. Eur Spine J. 2010; 19(12):2075–94. Epub 2010/07/06. https://doi.org/10.1007/s00586-010-1502-y PMID: 20602122; PubMed Central PMCID: PMC2997201.

29. National Guideline Centre (UK). Low back pain and sciatica in over 16s: assessment and management. London, UK: NICE; 2016 November.

30. CQUniversity Australia. 10,000 Steps Website 2016. Available from: https://www.10000steps.org.au/.

31. Fitbit. Make Fitness a Lifestyle with Flex; Fitbit, Inc. Available from: https://www.fitbit.com/au/flex.

32. Kongsvold AM. Validation of the AX3 accelerometer for detection of common daily activities and postures. Oslo, Norway: Norwegian University of Science and Technology; 2016.

33. Rowlands AV, Mirkes EM, Yates T, Clemen S, Davies M, Khunti K, et al. Accelerometer-assessed physical activity in epidemiology: are monitors equivalent? Medicine and science in sports and exercise. 2017; 50(2):257–65.

34. Kongsvold AM. Validation of the AX3 accelerometer for detection of common daily activities and postures. Oslo, Norway: Norwegian University of Science and Technology; 2016.

35. Godfrey A, Del Din S, Barry G, Mathers JC, Rochester L. Within trial validation and reliability of a single tri-axial accelerometer for gait assessment. Conf Proc IEEE Eng Med Biol Soc. 2014; 2014:5892–5. Epub 2015/01/09. https://doi.org/10.1109/EMBC.2014.6944969 PMID: 25571337.

36. Hickey A, Del Din S, Rochester L, Godfrey A. Detecting free-living steps and walking bouts: validating an algorithm for macro gait analysis. Physiological measurement. 2017; 38(1):N1–N15. Epub 2016/12/13. https://doi.org/10.1088/1066-5697/38/1/N1 PMID: 27941238.

37. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Arch Gen Psychiatry. 1961; 4:561–71. Epub 1961/06/01. https://doi.org/10.1001/archpsyc.1961.01710120031004 PMID: 13688369.

38. Richter P, Werner J, Heerlein A, Kraus A, Sauer H. On the validity of the Beck Depression Inventory. A review. Psychopathology. 1998; 31(3):160–8. Epub 1998/06/24. https://doi.org/10.1159/000066239 PMID: 9636945.
48. Sullivan MJL, Bishop SR, Pivik J. The Pain Catastrophizing Scale: development and validation. Psychol Assessment. 1995; 7(4):524–32. https://doi.org/10.1037/1040-3590.7.4.524 PubMed PMID: WOS:A1995TL18000014.

49. Osman A, Barrios FX, Kopper BA, Hauptmann W, Jones J, O'Neill E. Factor structure, reliability, and validity of the Pain Catastrophizing Scale. Journal of behavioral medicine. 1997; 20(6):589–605. Epub 1998/01/16. https://doi.org/10.1023/a:1025570508954 PMID: 9429990.

50. Osman A, Barrios FX, Gutierrez PM, Kopper BA, Merrifield T, Grittman L. The Pain Catastrophizing Scale: further psychometric evaluation with adult samples. Journal of behavioral medicine. 2000; 23(4):351–65. Epub 2000/09/14. https://doi.org/10.1023/a:1005548010037 PMID: 10984864.

51. Lundberg MKE, Styf J, Carlsson SG. A psychometric evaluation of the Tampa Scale for Kinesiophobia—from a physiotherapeutic perspective. Physiotherapy Theory Pract. 2009; 20(2):121–33. https://doi.org/10.1080/09593980490453002

52. Vlaeyen JW, Kole-Snijders AM, Boeren RG, van Eek H. Fear of movement/(re)injury in chronic low back pain and its relation to behavioral performance. Pain. 1995; 62(3):363–72. Epub 1995/09/01. https://doi.org/10.1016/0304-3959(94)00279-N PMID: 8657437.

53. Obeid JS, McGraw CA, Minor BL, Conde JG, Pawluk R, Lin M, et al. Procurement of shared data instruments for Research Electronic Data Capture (REDCap). J Biomed Inform. 2013; 46(2):259–65. Epub 2012/11/15. https://doi.org/10.1016/j.jbi.2012.10.006 PMID: 23149159; PubMed Central PMCID: PMCP3600393.

54. Esliger DW, Rowlands AV, Hurst TL, Catt M, Murray P, Eston RG. Validation of the GENEA accelerometer. Medicine and science in sports and exercise. 2011. https://doi.org/10.1249/MSS.0b013e31820513be PMID: 21088628

55. van Hees VT, Renström F, Wright A, Gradmark A, Catt M, Chen KY, et al. Estimation of daily energy expenditure in pregnant and non-pregnant women using a wrist-worn tri-axial accelerometer. PloS one. 2011; 6(7):e22922. https://doi.org/10.1371/journal.pone.0022922 PMID: 21829556

56. Thabane L, Ma J, Chu R, Cheng J, Ismaila A, Rios LP, et al. A tutorial on pilot studies: the what, why and how. BMC Medical Research Methodology. 2010; 10(1):1. https://doi.org/10.1186/1471-2288-10-1

57. Julious SA. Sample size of 12 per group rule of thumb for the Variance from a Pilot Sample. Biometrical Journal. 2005; 4(4):287–91.

58. Kieser M, Wassmer G. On the Use of the Upper Confidence Limit for the Variance from a Pilot Sample for Sample Size Determination. Biometrical Journal. 1996; 38(8):941–9. https://doi.org/10.1002/bimj.4710380806.

59. Gupta SK. Intention-to-treat concept: a review. Perspect Clin Res. 2011; 2(3):109–12. Epub 2011/09/08. https://doi.org/10.4103/2229-3485.83221 PMID: 21897887; PubMed Central PMCID: PMCP3159210.

60. Roth PL, Switzer FS, Switzer DM. Missing data in multiple item scales: a monte carlo analysis of missing data techniques. Organ Res Methods. 1999; 2(3):211–32. https://doi.org/10.1177/109442819923001

61. IBM Corp. IBM SPSS Statistics for Windows. Version 22.0 ed: IBM Corp; 2013.

62. Krein SL, Kadrir H, Hughes M, Kerr EA, Piette JD, Holleman R, et al. Pedometer-based internet-mediated intervention for adults with chronic low back pain: randomized controlled trial. J Med Internet Res. 2013; 15(8):e218. https://doi.org/10.2196/jmir.2605 PMID: 23969029; PubMed Central PMCID: PMCP3758050.

63. Smeets RJ, Vlaeyen JW, Kester AD, Knottenbus JA. Reduction of pain catastrophizing mediates the outcome of both physical and cognitive-behavioral treatment in chronic low back pain. The journal of pain. 2006; 7(4):261–71. Epub 2006/04/19. https://doi.org/10.1016/j.jpain.2005.10.011 PMID: 16618470.

64. Ogunlana MO, Odole AC, Adejumobi A, Odunaiya N. Catastrophising, pain, and disability in patients with nonspecific low back pain. Hong Kong Physiother J. 2015; 33(2):73–9. Epub 2015/04/16. https://doi.org/10.1016/j.hkj.2015.03.001 PMID: 30930571.

65. Edwards RR, Cahalan C, Mensing G, Smith M, Haythornthwaite JA. Pain, catastrophizing, and depression in the rheumatic diseases. Nature reviews Rheumatology. 2011; 7(4):216–24. Epub 2011/02/02. https://doi.org/10.1038/nrrheum.2011.2 PMID: 21283147.
69. Hanscom DA, Brox JI, Bunnage R. Defining the Role of Cognitive Behavioral Therapy in Treating Chronic Low Back Pain: An Overview. 2015; 5(6):496–504. https://doi.org/10.1055/s-0035-1567836 PMID: 26682100.

70. Nilsen TIL, Holtermann A, Mork PJ. Physical exercise, body mass index, and risk of chronic pain in the low back and neck/shoulders: longitudinal data from the nord-trøndelag health study. Am J Epidemiol. 2011; 174(3):267–73. https://doi.org/10.1093/aje/kwr087 PMID: 21633119

71. Alzahrani H, Shirley D, Cheng SWM, Mackey M, Stamatakis E. Physical activity and chronic back conditions: A population-based pooled study of 60,134 adults. J Sport Health Sci. 2019; 8(4):386–93. Epub 2019/07/25. https://doi.org/10.1016/j.jshs.2019.01.003 PMID: 31333893; PubMed Central PMCID: PMC6620421.

72. Cleland I, Kikhia B, Nugent C, Boytsov A, Hallberg J, Synnes K, et al. Optimal placement of accelerometers for the detection of everyday activities. Sensors (Basel, Switzerland). 2013; 13(7):9183–200. Epub 2013/07/23. https://doi.org/10.3390/s130709183 PMID: 23867744; PubMed Central PMCID: PMC3758644.